Development of DYR533, a highly selective and orally bioavailable inhibitor of DYRK1A toward the treatment of Alzheimer’s disease and/or Down syndrome

Samantha Rokey

Christopher Foley

Ramon Velazquez

Travis Dunckley

Arthur-Y Shaw

Bessie Meechoovet

Christopher Hulme

0 views
0 downloads

Powered byMorressier logo black

Discover more research and events on morressier.com